Compare IDEXX Laboratories, Inc. (IDXX) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Visa Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Visa Inc trades at $385.6 (market cap $704.20B). The key difference: Visa Inc is far larger — about 17.4× IDEXX Laboratories, Inc.'s market cap, and Visa Inc pays a 0.71% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Visa Inc for 115 Days on average.
| IDXX | V | |
|---|---|---|
Market Cap | $40.43B | $704.20B |
Volume | 692,164 | 6,405,857 |
Sector | Health | Financials |
52-Week High | $766.68 | $384.14 |
52-Week Low | $504.70 | $295.52 |
Typical Hold Time | 46 Days | 115 Days |
Enterprise Value | $41.32B | $714.78B |
Dividend Yield | — | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
Visa (V) trades at $385.45, up 3.59% today, with a bullish technical signal and strong analyst consensus. The stock shows robust fundamentals, including a 50.78% net income margin and consistent earnings beats. Recent news highlights Visa's AI-driven initiatives like Intelligent Commerce Connect and partnerships to advance stablecoin adoption, positioning it for future growth in digital payments.
Outlook remains positive with a consensus price target of $422.24, implying 9.5% upside. Risks include competitive fintech threats and regulatory pressures. The company's high profitability and strategic focus on AI and digital payments support long-term investment appeal, though valuation multiples are elevated.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
